Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs: Appraisal consultation document
DRAFT guidance does not recommend guselkumab, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to- or who cannot tolerate previous DMARDs, as it was not considered cost-effective use of NHS resources.
Source:
National Institute for Health and Care Excellence